Clinical Trial Update: A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden

View source ↗

Summary

A registry-based study in Sweden evaluates overall survival and treatment duration in metastatic castration-resistant prostate cancer patients treated with enza…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Xtandi (enzalutamide)

Snippet

Sponsor: Astellas Pharma a/s | Conditions: Metastatic Castration Resistant Prostate Cancer | Status: COMPLETED